The Beatson West of Scotland Cancer Centre

Glasgow G120YN

3 studies enrolling now · 27 studies all time

What they study most

ARID1A Gene Mutation, Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced/Metastatic Non-Small Cell Lung Cancer, Bladder Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Castration-Resistant Prostate Cancer, Chronic Lymphocytic Leukemia, Colorectal Cancer

Studies at this site

• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — Recruiting now
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting now
• Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors — Recruiting now
• A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer — Stopped early
• A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer — Running, not enrolling
• PALbociclib CoLlaborative Adjuvant Study — Running, not enrolling
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
• Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant — Running, not enrolling
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Running, not enrolling
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma — Running, not enrolling
• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Running, not enrolling
• Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) — Completed
• Study to Evaluate CCS1477 in Advanced Tumours — Completed
• Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer — Running, not enrolling
• A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment — Completed
• Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour — Completed
• Study of Continuous OSI-906 Dosing — Completed
• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma — Completed
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. — Completed
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy — Completed
• A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer — Completed
• A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function — Completed
• OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer — Completed
• A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment — Completed
• Phase I Study of OSI-930 and Erlotinib in Cancer Tumors — Completed